February 3rd 2023
February 1st 2023
January 24th 2023
Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes
Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.
Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.
“Reversing and preventing adverse lifestyle factors could potentially reduce the incidence and burden of rheumatoid arthritis, as well as alleviate its comorbidities,” investigators hypothesized.
Investigators measured pain intensity, the primary outcome, as well as physical function, isometric strength, quality of life, and fibromyalgia impact at baseline and the 6-month mark.
On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.
"Despite advances in SCD management and high-risk pregnancy care, at the national level, outcomes in this population have not improved since the last NIS analysis of data from 1999 to 2008," investigators write.